2024
Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
Weiss J, Yates S, Badar T, Patel A, Winer E, Litzow M, Cheng W, Lin C, Shallis R. Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax. Blood 2024, 144: 1489-1489. DOI: 10.1182/blood-2024-206670.Peer-Reviewed Original ResearchAcute myeloid leukemiaBody mass indexOverall response rateBody mass index groupsSecondary AMLObese ptsHypomethylating agentsEuropean LeukemiaNetMulti-centerOverall survivalMyeloid leukemiaRetrospective studyMass indexNewly diagnosed acute myeloid leukemiaVariable volume of distributionSecondary acute myeloid leukemiaAssociated with higher 90-day mortalityTreatment of acute myeloid leukemiaHigher 30-day mortalityMultivariate Cox regression modelInterquartile rangeComposite remission rateExtensive protein bindingKaplan-Meier methodRisk of early mortality
2022
The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting.
Riaz F, Zhu H, Cheng W, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Parikh R, Reuss J, Prsic E, Doroshow D. The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.28_suppl.300.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsRetrospective studyInpatient settingOutcome studiesPT outcomesStage IV solid malignancyYale-New Haven HospitalImaging-based responseMedian prior linesNon-curative intentOutcome of ptsCTLA-4 inhibitorsMulticenter retrospective studyPD-L1 expressionPoor clinical outcomeCare of patientsTime of administrationMount Sinai HospitalGeorgetown University HospitalHealth care systemICI administrationICI doseICI initiation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply